Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
INAF Stock Overview
PT Indofarma Tbk, together with its subsidiaries, manufactures and markets pharmaceutical products in Indonesia.
Risk Analysis
No risks detected for INAF from our risk checks.
Indofarma Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | Rp1,165.00 |
52 Week High | Rp3,490.00 |
52 Week Low | Rp1,100.00 |
Beta | -0.0094 |
1 Month Change | -13.70% |
3 Month Change | -42.61% |
1 Year Change | -47.76% |
3 Year Change | -69.34% |
5 Year Change | -72.26% |
Change since IPO | 468.29% |
Recent News & Updates
Shareholder Returns
INAF | ID Pharmaceuticals | ID Market | |
---|---|---|---|
7D | -5.3% | -0.4% | -1.0% |
1Y | -47.8% | 1.5% | 18.2% |
Return vs Industry: INAF underperformed the ID Pharmaceuticals industry which returned 0.5% over the past year.
Return vs Market: INAF underperformed the ID Market which returned 15.6% over the past year.
Price Volatility
INAF volatility | |
---|---|
INAF Average Weekly Movement | 4.8% |
Pharmaceuticals Industry Average Movement | 3.7% |
Market Average Movement | 6.3% |
10% most volatile stocks in ID Market | 12.2% |
10% least volatile stocks in ID Market | 3.0% |
Stable Share Price: INAF is not significantly more volatile than the rest of ID stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: INAF's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1918 | 1,253 | Arief Pramuhanto | https://indofarma.id |
PT Indofarma Tbk, together with its subsidiaries, manufactures and markets pharmaceutical products in Indonesia. The company trades in and distributes drugs, medical devices, medical supplies, extracts, and herbals; and operates laboratory. It also provides COVID-19 test services, including rapid diagnostic test antigen; reverse transcription polymerase chain reaction, and genose.
Indofarma Fundamentals Summary
INAF fundamental statistics | |
---|---|
Market Cap | Rp3.61t |
Earnings (TTM) | -Rp37.58b |
Revenue (TTM) | Rp2.90t |
1.2x
P/S Ratio-96.1x
P/E RatioIs INAF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
INAF income statement (TTM) | |
---|---|
Revenue | Rp2.90t |
Cost of Revenue | Rp2.46t |
Gross Profit | Rp442.87b |
Other Expenses | Rp480.46b |
Earnings | -Rp37.58b |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
Earnings per share (EPS) | -12.13 |
Gross Margin | 15.26% |
Net Profit Margin | -1.29% |
Debt/Equity Ratio | 117.6% |
How did INAF perform over the long term?
See historical performance and comparisonValuation
Is Indofarma undervalued compared to its fair value and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
7.1x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: INAF (IDR1165) is trading above our estimate of fair value (IDR1019.77)
Significantly Below Fair Value: INAF is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: INAF is unprofitable, so we can't compare its PE Ratio to the ID Pharmaceuticals industry average.
PE vs Market: INAF is unprofitable, so we can't compare its PE Ratio to the ID market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate INAF's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: INAF is overvalued based on its PB Ratio (7.1x) compared to the ID Pharmaceuticals industry average (2.5x).
Future Growth
How is Indofarma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
15.4%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Indofarma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Indofarma performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
37.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: INAF is currently unprofitable.
Growing Profit Margin: INAF is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: INAF is unprofitable, but has reduced losses over the past 5 years at a rate of 37.9% per year.
Accelerating Growth: Unable to compare INAF's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INAF is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.8%).
Return on Equity
High ROE: INAF has a negative Return on Equity (-7.39%), as it is currently unprofitable.
Financial Health
How is Indofarma's financial position?
Financial Health Score
4/6Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: INAF's short term assets (IDR1,411.4B) exceed its short term liabilities (IDR1,045.2B).
Long Term Liabilities: INAF's short term assets (IDR1,411.4B) exceed its long term liabilities (IDR458.4B).
Debt to Equity History and Analysis
Debt Level: INAF's net debt to equity ratio (42.7%) is considered high.
Reducing Debt: INAF's debt to equity ratio has increased from 73.3% to 117.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable INAF has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: INAF is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 35.4% per year.
Dividend
What is Indofarma current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate INAF's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate INAF's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if INAF's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if INAF's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: INAF is not paying a notable dividend for the ID market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as INAF has not reported any payouts.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.0yrs
Average management tenure
CEO
Arief Pramuhanto (59 yo)
3yrs
Tenure
Rp2,084,000,000
Compensation
Mr. Arief Pramuhanto has been President Director of PT Indofarma (Persero) Tbk since May 7, 2019. Mr. Pramuhanto was General Affairs and Human Capital Director at PT Kimia Farma (Persero) Tbk since April 2...
CEO Compensation Analysis
Compensation vs Market: Arief's total compensation ($USD142.24K) is about average for companies of similar size in the ID market ($USD199.05K).
Compensation vs Earnings: Arief's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: INAF's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
Experienced Board: INAF's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
PT Indofarma Tbk's employee growth, exchange listings and data sources
Key Information
- Name: PT Indofarma Tbk
- Ticker: INAF
- Exchange: IDX
- Founded: 1918
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: Rp3.611t
- Shares outstanding: 3.10b
- Website: https://indofarma.id
Number of Employees
Location
- PT Indofarma Tbk
- Jalan Indofarma No. 1
- Cikarang Barat
- Bekasi
- Jawa Barat
- 17530
- Indonesia
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/05/18 00:00 |
End of Day Share Price | 2022/05/18 00:00 |
Earnings | 2021/12/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.